AN2 Therapeutics Inc (ANTX)

1.30 -0.05 (-3.70%) USD  |  NASDAQ  |  Jan 08, 16:00
1.30 0.00 (0.00%) After-Hours: 20:00
More

AN2 Therapeutics SG&A Expense (Quarterly): 3.484M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for ANTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Biomarin Pharmaceutical Inc 253.50M
Arbutus Biopharma Corp 4.537M
GlycoMimetics Inc 4.006M
FibroGen Inc 17.55M
Cidara Therapeutics Inc 4.965M